ipilimumab,nivolumab
bms
['nivo', 'rcc,(-irccs),(-srcc),(-urcc)', 'ipilimumab', 'nivolumab']
patients with localized recall cell carcinoma did not have improved disease-free survival when given adjuvant nivolumab plus ipilimumab vs placebo. #rccsm #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.